

Diaceutics PLC
("Diaceutics" or the "Company")

Issue of Share Options

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of 0.2p each in the Company ("Share Options") on 30 June 2020, to certain members of the Company's senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the IPO and are governed by the rules of the Company's Employee Share Option Plan ("ESOP").

Share Options were granted as follows:

Name	Number of Share Options granted	Total no. of ordinary shares under option post grant	% of existing issued share capital
Damian Thornton (COO and PDMR)	4,200	102,704	0.12%
Jordan Clark (CTO and PDMR)	4,200	76,114	0.09%
Susanne Munksted (CPO and PDMR)	4,200	70,672	0.08%

A further 214,500 Share Options were granted to 51 employees, each of whom received 4,200 Share Options.

The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 0.2p per share being the nominal value of the share.

Following the grant the total number of share options outstanding granted to the Company's Directors, senior management team and key employees is 1,790,762, representing approximately 2.13% of the Company's current issued share capital of 84,068,923.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com

via Walbrook PR

Cenkos Securities plc (Nominated adviser and broker)

Callum Davidson / Giles Balleny
Michael Johnson (Sales)

+44 (0)207 397 8900

Walbrook PR

Anna Dunphy
Paul McManus

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Mob: +44 (0)7876 741 001

Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company has worked on every precision medicine brought to market and provides services to 36 of the world's leading pharmaceutical companies. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Damian Thornton
2 Reason for notification		
a.	Position/Status	Chief Operating Officer
b.	Initial notification/	Initial

	Amendment					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>4,200</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	4,200
Price(s)	Volume(s)					
Exercise price of 0.2p per share	4,200					
e.	Date of the transaction	30 June 2020				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1	Details of the person discharging managerial responsibilities/person closely associated					
a.	Name	Jordan Clark				
2	Reason for notification					
a.	Position/Status	Chief Technology Officer				
b.	Initial notification/ Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)		
Price(s)	Volume(s)					

		<table border="1"> <tr> <td>Exercise price of 0.2p per share</td> <td>4,200</td> </tr> </table>	Exercise price of 0.2p per share	4,200
Exercise price of 0.2p per share	4,200			
e.	Date of the transaction	30 June 2020		
f.	Place of the transaction	Outside a trading venue		

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Susanne Munksted				
2 Reason for notification						
a.	Position/Status	Chief Precision Officer				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Grant of share options				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Exercise price of 0.2p per share</td> <td>4,200</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Exercise price of 0.2p per share	4,200
Price(s)	Volume(s)					
Exercise price of 0.2p per share	4,200					
e.	Date of the transaction	30 June 2020				
f.	Place of the transaction	Outside a trading venue				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.rns.com.

END

DSHMZGGNVZDGGZM